Biologics joining fight against asthma


Should you be unfortunate enough to suffer from asthma, things are looking up. There are new biological therapies out there that “attack” asthma in novel ways. They are effective and are badly needed. The impact of the disease on people afflicted with it is probably more severe than you think. It’s not as simple as carrying an inhaler around.

Xolair was the first biological drug approved for moderate-to-severe asthma. It has a unique mechanism of action: binding to IgE, the “allergic antibodies” in our blood. People who have high IgE levels are allergic.

Cinqair and Nucala are monoclonal antibodies which operate by a mechanism which is different from that of Xolair. They are considered to be more “heavy hitters” than Xolair, and were designed to treat a different form of asthma called eosinophilic asthma – a severe form of the disease.

Dupixent is not an approved asthma drug; it got the nod from the FDA earlier in 2017 for a different allergic response – eczema…So, why is it here? Because Dupixent also works against asthma, and, apparently quite well.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: The Arsenal Against Asthma Grows: Biologics